Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Nutrition. 2014 Mar 28;30(0 0):S4–S10. doi: 10.1016/j.nut.2014.03.009

Figure 4. DMC-2 from 5011 Nutrasorb is more bioavailable than from PMI-5011.

Figure 4

Representative chromatograms show LC-MC analysis of: (A) serum collected from mouse treated with 66% Labrasol, (B) serum collected from a DMC-2-treated mouse (500 mg/kg in 66% Labrasol) showing the glucuronic acid conjugate of DMC-2 (m/z 447) and, (C) serum collected from a DMC-2-treated mouse (500 mg/kg in 66% Labrasol) hydrolyzed with β-glucuronidase to obtain DMC-2 (m/z 271). To compare bioavailability, C57BL/6 mice were orally administered 500 mg/kg of PMI-5011 (n=7) or Nutrasorb-5011 (n=6). Serum was collected after 2 h, hydrolyzed, and analyzed for DMC-2 content by LC-MS as described in methods. The data is presented as (D) the amount of DMC-2 measured in serum (ng) and (E) percentage of the DMC-2 absorbed in serum relative to the amount dosed. Both doses were comprised of the same amount of treatment material (tmt) with different amounts of DMC-2. Two-tailed t-test **= p< 0.01.